UOC
CDMO

UBS O'Connor’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

UBS O'Connor’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-150,900
Closed -$441K – 382
2018
Q1 		$441K Buy
+150,900
New +$466K 0.01% 268

Other funds holding CDMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BP
Bandera Partners New York $221M AUM 10.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SIC
Schwartz Investment Counsel Plymouth, Michigan $2.82B AUM 13.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS O'Connor's CDMO Position: Q2 2018 in Review

UBS O'Connor sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q2 2018, closing a stake of 150,900 shares — an estimated $441K sold.

UBS O'Connor first reported a position in CDMO in Q1 2018 and held it in 1 quarter. The position peaked at $441K in Q1 2018. 81 funds tracked by Wall St. Rank hold CDMO as of Q2 2018.

  • UBS O'Connor reported no remaining Avid Bioservices, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • UBS O'Connor sold 150,900 Avid Bioservices, Inc. Common Stock shares in Q2 2018, an estimated $441K.
  • UBS O'Connor first reported a position in Avid Bioservices, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • UBS O'Connor's Avid Bioservices, Inc. Common Stock position peaked at $441K in Q1 2018.
  • 81 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q2 2018.

Based on UBS O'Connor's 13F filing for Q2 2018, filed 14 Aug 2018.